Transthyretin Amyloidosis Treatment Market Size & Growth Forecast 2027–2036, By Segments (Type, Disease Type, Distribution Channel, Route of Administration, Drug Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Transthyretin Amyloidosis Treatment Market size was valued at USD 11.74 Billion in 2026 and is projected to grow at 8.27% CAGR from 2027 to 2036, crossing USD 25.99 Billion by 2036. The industry revenue for 2027 is estimated at USD 12.56 Billion.
Get more details on this report
Request Free Sample ReportTransthyretin Amyloidosis Treatment Market Intelligence Snapshot
Regional Market Dynamics
- North America held 40.61% in 2026, supported by advanced healthcare infrastructure, specialized rare-disease networks, greater disease awareness, and access to targeted treatments.
- Europe is the fastest-growing region, supported by improving diagnosis, stronger referral pathways, expanding specialized services, and greater access to innovative therapies.
Segment Momentum
- Hereditary transthyretin amyloidosis accounted for 59.23% of the market share in 2026, supported by increased genetic testing, stronger disease awareness, earlier diagnosis, and wider availability of targeted treatment options.
- Online pharmacies are expanding quickly as digital healthcare, telehealth, home delivery services, and prescription fulfillment platforms improve medication accessibility and patient support for long-term treatment management.
Market Expansion Drivers
- Increasing diagnosis of ATTR cardiomyopathy driving demand for targeted disease-modifying therapies
- Advancements in gene-silencing therapies improving long-term treatment outcomes for rare diseases
- Expansion of non-invasive diagnostic technologies enabling earlier ATTR disease detection and treatment initiation
Leading Market Participants
- Prominent players in the transthyretin amyloidosis treatment market include Pfizer Inc. (United States), Alnylam Pharmaceuticals, Inc. (United States), Ionis Pharmaceuticals, Inc. (United States), AstraZeneca plc (United Kingdom), BridgeBio Pharma, Inc. (United States), Prothena Corporation plc (United States), Intellia Therapeutics, Inc. (United States), Neurimmune AG (Switzerland), Akcea Therapeutics (United States), Bristol Myers Squibb Company (United States)
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 11.74 Billion
- 2027 Estimated Market Size: USD 12.56 Billion
- Projected Market Size: USD 25.99 Billion by 2036
- Growth Forecast: 8.27% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Europe
- Core Revenue Segment: ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) (Type) | Hereditary Transthyretin Amyloidosis (Disease Type) | Hospital Pharmacy (Distribution Channel) | Oral (Route of Administration) | Tafamidis (Drug Type)
- Emerging Opportunity Segment: ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) (Type) | Wild Type Transthyretin Amyloidosis (Disease Type) | Online Pharmacy (Distribution Channel) | Parenteral (Route of Administration) | Patisiran (Drug Type)
Market Growth Drivers and Industry Trends
Increasing diagnosis of ATTR cardiomyopathy driving demand for targeted disease-modifying therapies
Improved clinical awareness and greater recognition of transthyretin amyloidosis among healthcare professionals are leading to higher diagnosis rates of ATTR cardiomyopathy. The transthyretin amyloidosis treatment market growth is driven by the increasing identification of eligible patients who require therapies designed to address the underlying disease process rather than only managing symptoms. Expanded screening efforts and improved understanding of disease presentation are enabling clinicians to initiate more appropriate treatment strategies for individuals affected by this progressive condition.
Advancements in gene-silencing therapies improving long-term treatment outcomes for rare diseases
Innovations in gene-silencing technologies are transforming the treatment landscape for hereditary and acquired transthyretin amyloidosis by targeting disease mechanisms at the molecular level. Within the transthyretin amyloidosis treatment market, these therapeutic advances are expanding options for reducing abnormal protein production while supporting improved disease management and long-term clinical outcomes. Ongoing progress in precision medicine and RNA-based therapeutic approaches is strengthening confidence in targeted treatments for patients with rare and complex disorders.
Expansion of non-invasive diagnostic technologies enabling earlier ATTR disease detection and treatment initiation
The availability of advanced non-invasive diagnostic methods is improving the ability of clinicians to identify transthyretin amyloidosis without relying solely on invasive procedures. This trend will drive the transthyretin amyloidosis treatment market growth by supporting earlier diagnosis, timely therapeutic intervention, and more efficient patient management throughout the care pathway. Enhanced diagnostic accessibility also helps differentiate ATTR from other cardiovascular and neurological disorders, allowing physicians to establish appropriate treatment plans with greater confidence.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing diagnosis of ATTR cardiomyopathy driving demand for targeted disease-modifying therapies | 2.6% | High | North America, Europe | High | Near Term |
| Advancements in gene-silencing therapies improving long-term treatment outcomes for rare diseases | 2.8% | High | North America, Asia Pacific | High | Mid Term |
| Expansion of non-invasive diagnostic technologies enabling earlier ATTR disease detection and treatment initiation | 2.7% | High | Europe, North America | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
In the transthyretin amyloidosis treatment market, North America held the largest share of 40.61% in 2026, supported by advanced healthcare infrastructure, greater awareness of transthyretin amyloidosis, and improved access to specialized diagnostic and treatment services. The region benefits from established rare-disease care networks and growing clinical attention toward earlier identification of hereditary and wild-type forms of the disease. Increasing investment in precision medicine and the availability of targeted treatment approaches are also strengthening treatment adoption, while an aging population and rising recognition of cardiac and neurological manifestations are expanding the addressable patient base.
Europe (Fastest-Growing Region)
Europe is expected to witness the fastest growth, driven by improving diagnosis of transthyretin amyloidosis, expanding access to specialized rare-disease services, and greater emphasis on earlier intervention. Healthcare systems across the region are increasingly strengthening referral pathways for patients with unexplained cardiomyopathy and neuropathy, supporting more timely identification of the condition. Growing awareness among clinicians, advances in genetic and molecular diagnostics, and efforts to improve access to innovative therapies are expected to further support market expansion.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
United States 🇺🇸
Rare Disease InnovationThe U.S. transthyretin amyloidosis treatment market benefits from active rare disease research, expanding diagnostic awareness, and broader adoption of targeted therapies. Companies are strengthening specialist engagement and improving patient identification to support timely treatment access across cardiology and neurology care pathways.
Germany 🇩🇪
Specialized Care NetworksGermany advances transthyretin amyloidosis treatment through coordinated specialist centers and structured diagnostic pathways. Companies are working with referral networks to improve early diagnosis while supporting adoption of innovative therapies for eligible patient populations.
Japan 🇯🇵
Precision Diagnosis IntegrationJapan emphasizes early recognition of transthyretin amyloidosis alongside the integration of precision therapies into specialized clinical practice. The market encourages collaboration between academic institutions and healthcare providers to improve diagnostic confidence and treatment continuity.
South Korea 🇰🇷
Genomic Medicine ExpansionSouth Korea is incorporating advanced genetic testing and specialist care into transthyretin amyloidosis management. Market participants are supporting physician education and improving access to targeted therapies that align with evolving precision medicine initiatives.
France 🇫🇷
Coordinated Rare CareFrance supports transthyretin amyloidosis treatment through dedicated rare disease programs and multidisciplinary clinical management. Companies are focusing on improving patient referral pathways and demonstrating long-term therapeutic value within specialized healthcare settings.
Italy 🇮🇹
Specialist Referral DevelopmentItaly continues to strengthen transthyretin amyloidosis treatment through expanded specialist referrals and improved disease awareness. Manufacturers are collaborating with clinical centers to facilitate earlier diagnosis and broader integration of targeted therapies into routine patient management.
Segment Leadership and Growth Trends
Transthyretin Amyloidosis Treatment Market Share (%), by Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportType Segment Analysis: ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) (Largest & Fastest-Growing Segment)
The transthyretin amyloidosis treatment market was led by the ATTR amyloidosis with cardiomyopathy (ATTR-CM) segment, which accounted for 76.51% of the market share in 2026 while also representing the fastest-growing segment. Its strong position is supported by increasing recognition of cardiac manifestations associated with transthyretin amyloidosis, improving diagnostic capabilities, and expanding availability of disease-specific therapies. Greater clinical awareness, enhanced screening among at-risk populations, and continued progress in targeted treatment approaches are further strengthening demand for therapies addressing ATTR-CM, reinforcing its market leadership.
Disease Type Segment Analysis: Hereditary Transthyretin Amyloidosis (Largest Segment) vs Wild Type Transthyretin Amyloidosis (Fastest-Growing Segment)
Hereditary transthyretin amyloidosis held the largest market share of 59.23% in 2026, supported by increasing identification of genetically inherited cases and growing availability of specialized diagnostic testing. Advancements in genetic screening, improved disease awareness among healthcare professionals, and the availability of targeted therapeutic options have encouraged earlier diagnosis and treatment, contributing to the segment's continued leadership.
Within the transthyretin amyloidosis treatment market, the wild type transthyretin amyloidosis segment is expected to experience the fastest growth as awareness of age-related cardiac amyloidosis continues to improve. Expanded use of advanced imaging techniques, greater recognition of disease symptoms in older patient populations, and increasing access to effective therapeutic interventions are driving higher diagnosis rates and supporting broader adoption of treatment options for this patient group.
Distribution Channel Segment Analysis: Hospital Pharmacy (Largest Segment) vs Online Pharmacy (Fastest-Growing Segment)
Hospital pharmacy accounted for 47.28% of the market share in 2026, making it the largest distribution channel segment. Its dominance is driven by the specialized nature of transthyretin amyloidosis treatment, which requires expert clinical supervision, multidisciplinary care, and access to advanced therapies typically administered through hospital-based healthcare systems. Hospital pharmacies also facilitate coordinated patient management, ensuring appropriate dispensing and monitoring of complex treatment regimens.
The online pharmacy segment is anticipated to witness the fastest growth in the transthyretin amyloidosis treatment market as digital healthcare services continue to expand and patients increasingly seek convenient medication access. Improvements in prescription fulfillment platforms, home delivery services, and digital patient support programs are enhancing accessibility, while broader adoption of telehealth services is encouraging greater utilization of online pharmacy channels.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type | ATTR Amyloidosis with Polyneuropathy (ATTR-PN), ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) | ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) | ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) |
| Disease Type | Hereditary Transthyretin Amyloidosis, Wild Type Transthyretin Amyloidosis | Hereditary Transthyretin Amyloidosis | Wild Type Transthyretin Amyloidosis |
| Distribution Channel | Hospital Pharmacy, Retail Drug Stores, Online Pharmacy | Hospital Pharmacy | Online Pharmacy |
| Route of Administration | Oral, Parenteral | Oral | Parenteral |
| Drug Type | Tafamidis, Patisiran, Inotersen, Others | Tafamidis | Patisiran |
Competitive Landscape and Market Positioning
Leading companies in the transthyretin amyloidosis treatment market:
- Pfizer, Inc. (United States)
- Alnylam Pharmaceuticals, Inc. (United States)
- Ionis Pharmaceuticals, Inc. (United States)
- AstraZeneca plc (United Kingdom)
- BridgeBio Pharma, Inc. (United States)
- Prothena Corporation plc (United States)
- Intellia Therapeutics, Inc. (United States)
- Neurimmune AG (Switzerland)
- Akcea Therapeutics (United States)
- Bristol Myers Squibb Company (United States)
Scientific advancement is redefining competitive priorities as developers pursue therapies capable of addressing the underlying mechanisms of transthyretin amyloidosis rather than focusing solely on symptom management. Competition increasingly revolves around demonstrating meaningful clinical benefit across different stages of disease while improving long-term treatment convenience and expanding eligibility for broader patient populations. As diagnostic capabilities improve and earlier identification becomes more common, market participants are aligning development strategies with integrated care pathways, reinforcing the importance of clinical evidence, patient monitoring support, and specialized treatment expertise in establishing competitive differentiation.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. (United States) | |||||||
| Alnylam Pharmaceuticals Inc. (United States) | |||||||
| Ionis Pharmaceuticals Inc. (United States) | |||||||
| AstraZeneca plc (United Kingdom) | |||||||
| BridgeBio Pharma Inc. (United States) | |||||||
| Prothena Corporation plc (United States) | |||||||
| Intellia Therapeutics Inc. (United States) | |||||||
| Neurimmune AG (Switzerland) | |||||||
| Akcea Therapeutics (United States) | |||||||
| Bristol Myers Squibb Company (United States) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Alnylam Pharmaceuticals | Nov-24 | Alnylam Pharmaceuticals announced that the U.S. Food and Drug Administration accepted its supplemental New Drug Application for vutrisiran targeting transthyretin amyloidosis with cardiomyopathy, supported by clinical data and assigned a PDUFA target action date of March 23, 2025. |
| Wainzua | Oct-24 | Wainzua received a positive recommendation from the European Medicines Agency Committee for Medicinal Products for Human Use for treating hereditary transthyretin-mediated amyloidosis, backed by Phase III trial data demonstrating sustained improvements in neuropathy symptoms and patient quality of life. |
| Alnylam Pharmaceuticals | Jun-22 | Alnylam Pharmaceuticals received U.S. Food and Drug Administration authorization for AMVUTTRA to treat polyneuropathy of hereditary transthyretin-mediated amyloidosis, enabling the company to scale commercialization and expand its customer base. |
| AstraZeneca | Jan-22 | AstraZeneca was granted Orphan Drug Designation by the U.S. Food and Drug Administration for eplontersen to support the treatment of transthyretin-mediated amyloidosis, broadening the company's therapeutic portfolio. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Transthyretin Amyloidosis Treatment Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Treatment Line | First-Line Treatment, Second-Line Treatment, Third-Line and Later Treatment |
| Disease Stage | Early-Stage Disease, Moderate-Stage Disease, Advanced-Stage Disease |
| Treatment Setting | Hospital-Based Care, Specialty Clinics, Outpatient Care, Home-Based Care |
Transthyretin Amyloidosis Treatment Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Diagnostic Delay Reduction Strategy |
|
| Treatment Sequencing & Patient Management |
|
| Therapy Modality Evolution |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market valuation of transthyretin amyloidosis treatment?
How is the transthyretin amyloidosis treatment industry size expected to evolve during the forecast period?
How is earlier ATTR diagnosis influencing treatment market expansion?
Why are gene-silencing therapies becoming strategically important in transthyretin amyloidosis treatment?
Why does hereditary transthyretin amyloidosis lead the disease type segment?
What is driving the rapid growth of online pharmacies in the transthyretin amyloidosis treatment market?
Why does North America lead the transthyretin amyloidosis treatment market?
How is Europe driving growth in transthyretin amyloidosis treatment?
Which companies dominate the transthyretin amyloidosis treatment landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization